



ASX Announcement

5 April 2024

## Patent Infringement Case Dismissed

Mach7 Technologies Limited (“M7T” or “the Company”) (ASX:M7T), a company specialising in innovative imaging software solutions, today advises that the patent infringement lawsuit brought by AI Visualize, Inc. has been dismissed on appeal.

On 4 April 2024,<sup>1</sup> the United States Court of Appeals for the Federal Circuit affirmed a lower court’s dismissal of patent infringement claims asserted by AI Visualize, Inc., a Texas Corporation against Nuanca Communications, Inc. and Mach7 Technologies, Inc., a wholly-owned subsidiary of Mach7 Technologies Limited.<sup>2</sup>

In affirming the decision of the United States District Court for the District of Delaware, the Court of Appeals held that the subject patent claims “are patent ineligible because they are directed to an abstract idea and fail to transform that abstract idea into patent-eligible subject matter.”

In doing so, the Court confirmed that Mach7 Technologies, Inc. did not infringe on any patents.

M7T is pleased with the affirmation of this dismissal and the closure of this legal action.

### Released on authority of the Board by:

Mike Lampron  
Managing Director and Chief Executive Officer

### For more information, contact:

**Investor Relations**  
Françoise Dixon  
+61 (0) 412 292 977  
[ir@mach7t.com](mailto:ir@mach7t.com)

---

<sup>1</sup> United States time

<sup>2</sup> In July 2022, Mach7 announced that the United States District Court for the District of Delaware had dismissed AI Visualize’s claims of wilful infringement on the grounds that the patents were not eligible for patenting. In August 2022, Mach 7 received notice that AI Visualize had appealed the dismissal to the United States Court of Appeals for the Federal Circuit. The appeal was heard in October 2023.



## ASX Announcement

### About Mach7 Technologies

Mach7 Technologies (ASX:M7T), founded in 2007, is a medical imaging systems provider that develops innovative image management and viewing solutions for healthcare organizations. The core of these offerings is the Mach7 Enterprise Imaging Solution, encompassing Enterprise Data Management, Enterprise Diagnostic Viewing and Departmental Workflow applications. Mach7's Enterprise Data Management solution, consisting of a powerful Vendor Neutral Archive (VNA) and data administration tools, allows for the fast storage, access, retrieval and viewing of images across a healthcare network with connectivity to the Cloud. In July 2020, Mach7 acquired Client Outlook and the eUnity Enterprise Diagnostic Viewing technology to augment Mach7's Enterprise Data Management and Departmental Workflow applications. eUnity is a zero-footprint, FDA-approved, image viewing solution that makes images accessible on any workstation. This offers healthcare professionals consolidated access to all patient images and data, ensuring radiologists and clinical staff have timely access to the right information to diagnose and treat patients. Uniquely, the company also gives customers independence to deploy its solutions either on a component basis or in a unified comprehensive platform. With more than 165 customers across 15 different countries, Mach7 has built a global network of diverse customers that range from expansive Integrated Delivery Networks, National Health Systems, medical research facilities, and large academic medical institutions to regional community hospitals, private radiology practices, and independent provider groups. Visit [Mach7t.com](http://Mach7t.com).

### Forward-looking statements

This announcement may contain forward-looking statements regarding the Company's financial position, business strategy and objectives (rather than being based on historical or current facts). Any forward-looking statements are based on the current beliefs of the Company's management as well as assumptions made by, and information currently available to, the Company's management. Forward-looking statements are inherently uncertain and must be read accordingly. There can be no assurance that some or all of the underlying assumptions will prove to be valid.

All data presented in this announcement reflects the current views of the Company with respect to future events. Forward-looking statements are subject to risk, uncertainties and assumptions relating to the operations, results of operations, growth strategy and liquidity of the Company. To the maximum extent permitted by law, the Company, its officers, employees and agents do not accept any obligation to release any updates or revisions to the information (including any forward-looking statements) in this announcement to reflect any change to expectations or assumptions; and disclaim all responsibility and liability for any loss arising from reliance on this announcement or its contents.

